



Hansch analysis by QSAR model of curcumin and eight of its transformed derivatives with antimicrobial activity against *Staphylococcus aureus*

[Análisis Hansch mediante modelo QSAR de curcumina y ocho de sus derivados transformados con actividad antimicrobiana contra *Staphylococcus aureus*]

Dini Kesuma¹, Galih Satrio Putra^{2*}, Yahmin Yahmin², Sumari Sumari², Anisa Oktaviana Putri², Farida Anwari³, Novynanda Salmasfatah⁴, Melanny Ika Sulistyowaty⁵

¹Department of Pharmaceutical Chemistry, Faculty of Pharmacy University of Surabaya, Surabaya, Indonesia.

²Department of Chemistry, Faculty of Mathematics and Natural Sciences, State University of Malang, Indonesia.

³Pharmaceutical Chemistry Department, University of Anwar Medika, Sidoarjo, Indonesia.

⁴Institute of Technology, Science and Health RS Dr. Soepraoen, Malang, Indonesia.

⁵Department of Pharmaceutical Sciences, Faculty of Pharmacy Airlangga University, Surabaya, Indonesia.

*E-mail: galih.satrio.fmipa@um.ac.id

Abstract

Context: In the last decade, antimicrobial resistance cases have been widespread. The discovery and development of new drugs need to be done to overcome the case. Some research has found that some compounds, which are curcumin transformation derivatives, are able to inhibit the growth of *Staphylococcus aureus*.

Aims: To evaluate the development of antimicrobial candidates of curcumin versus *S. aureus*.

Methods: The *in silico* approach method, along with the QSAR technique, plays an important role in the process of discovery and development of new drugs. In this study, we focused on developing curcumin transformation derivatives that are much more potent by making the best QSAR equation of curcumin and eight curcumin transformation derivatives that have been tested *in vitro* for their antimicrobial activity against *Staphylococcus aureus*.

Results: The best QSAR equation was obtained from curcumin transformation derivatives as antimicrobial activity against *S. aureus*, with pMIC = 0.812 (\pm 0.162)EHOMO +5.443 (\pm 1.659) (n = 9; Sig = 0.002; R = 0.884; R² = 0.782; F = 25.153; Q² = 0.57).

Conclusions: In this study, an increase in the antimicrobial activity of curcumin transformation derivatives against *S. aureus* by increasing EHOMO was observed. The best QSAR equation can be a tool to obtain a more potential new chemical structure model and reduce trials and errors.

Keywords: antibacterial; curcumin; molecular docking; QSAR; transformation.

Resumen

Contexto: En la última década se han generalizado los casos de resistencia a los antimicrobianos. Es necesario descubrir y desarrollar nuevos fármacos para superar el caso. Algunas investigaciones han descubierto que algunos compuestos, que son derivados de la transformación de la curcumina, son capaces de inhibir el crecimiento de *Staphylococcus aureus*.

Objetivos: Evaluar el desarrollo de candidatos antimicrobianos de la curcumina contra *S. aureus*.

Métodos: El método de aproximación *in silico* con la técnica QSAR desempeña un papel importante en el proceso de descubrimiento y desarrollo de nuevos fármacos. En este estudio, nos centramos en el desarrollo de derivados de transformación de la curcumina que sean mucho más potentes realizando la mejor ecuación QSAR de la curcumina y ocho derivados de transformación de la curcumina que han sido probados *in vitro* por su actividad antimicrobiana contra *S. aureus*.

Resultados: Se obtuvo la mejor ecuación QSAR de los derivados de transformación de la curcumina como actividad antimicrobiana contra *S. aureus*, con pMIC = 0,812 (\pm 0,162)EHOMO +5,443 (\pm 1,659) (n = 9; Sig = 0,002; R = 0,884; R² = 0,782; F = 25,153; Q² = 0,57).

Conclusiones: En este estudio se observó un aumento de la actividad antimicrobiana de los derivados de transformación de curcumina frente a *S. aureus* mediante el aumento de EHOMO. La mejor ecuación QSAR puede ser una herramienta para obtener un nuevo modelo de estructura química más potencial y reducir los ensayos y errores.

Palabras Clave: antibacteriano; curcumina; acoplamiento molecular; QSAR; transformación.

ARTICLE INFO

Received: January 6, 2024.

Accepted: April 29, 2024.

Available Online: May 23, 2024.

AUTHOR INFO

ORCID:

[0000-0003-4192-3621](https://orcid.org/0000-0003-4192-3621) (GSP)

[0000-0002-1788-2113](https://orcid.org/0000-0002-1788-2113) (SS)

[0000-0002-9510-6822](https://orcid.org/0000-0002-9510-6822) (MIS)

INTRODUCTION

Staphylococcus aureus is an opportunistic gram-positive bacterium that often infects skin and upper respiratory tract infections in humans. Some infections caused by *Staphylococcus aureus* include septic shock (56%), pneumonia (32%), endocarditis (19%), bacteremia (10%), and cellulitis (6%) (Green et al., 2012). Methicillin is a beta-lactam antibiotic that is very sensitive for testing resistance in *Staphylococcus aureus*. Methicillin is only used *in vitro* and is not widely used clinically because methicillin has strong nephrotoxic side effects. In the last decade, many cases of *Staphylococcus aureus* reported were resistant to methicillin or are called methicillin-resistant *Staphylococcus aureus* (MRSA) (Green et al., 2012; Larsen et al., 2022; Mun et al., 2014).

To resolve the problem of MRSA cases, many researchers synthesize new compounds or use phytochemicals to find compounds that have more potential against MRSA with minimal side effects (Boehlich et al., 2020; Masumi et al., 2022; Mun et al., 2014; Zhang et al., 2018). The phytochemical that was very popularly used is curcumin (Mun et al., 2014). Curcumin is a major phytochemical often found in *Curcuma longa* L. or *Curcuma domestica* Valetton (Zingiberaceae family) (Teow et al., 2016). Various pharmacological activities of curcumin have been widely reported, including its antimicrobial, antidiabetic, anti-inflammatory, anticancer, and antioxidant activity (Teow et al., 2016).

In terms of antibacterial activity, curcumin has been reported to affect several bacteria, such as *Staphylococcus aureus*, *Trichophyton gypseum*, *Salmonella paratyphi*, and *Mycobacterium tuberculosis* (Schraufstatter and Bernt, 1949). Curcumin has great potential against MRSA (Mun et al., 2014). The weakness of curcumin, which was easily degraded due to the presence of a double H-alpha ketone group that can undergo keto-enol tautomeric and then undergo au-


toxidation to become bicyclopentadione derivative, as shown in Fig. 1 (Gordon et al., 2015; Schiener et al., 2015). Therefore, several studies have attempted to close the H-alpha biketone functional group in curcumin into a closed ring structure so that it is made much stronger and has the potential to against MRSA (Hamed et al., 2013; Teow et al., 2016).



MRSA resists beta-lactam antibiotics due to its low binding affinity to the penicillin-binding protein receptor penicillin-binding protein 2a (PBP2a) encoded by the *mecA* gene determinant. MRSA requires the *mecA* gene to reduce the sensitivity of the PBP2a receptor to beta-lactam antibiotics (Masumi et al., 2022; Teow et al., 2016). Therefore, this research focuses on an *in silico* study of several curcumin derivatives designed through the QSAR process on the PBP2a receptor (PDB ID: 4DKI) (Hamed et al., 2013; Lovering et al., 2012; Putra et al., 2023).

MATERIAL AND METHODS

QSAR procedure

The QSAR procedure that was conducted in this study was through ligand-based drug design (LBDD). This study used three processes to obtain the best QSAR equation, namely first collecting molecular descriptor data from various software. The second is to perform multivariate analysis through the multiple linear regression (MLR) method, Pearson correlation, and Z value, along with the determination of the best QSAR equation by internal validation method (r , R^2 , F , σ , Q^2) (Gramatica 2007; Putra et al., 2023). Finally, after obtaining the best QSAR equation, it is then used to design a new, more potential compound model and *in silico* study for pharmacokinetic prediction (ADMET) as well as molecular docking was redone on *Staphylococcus aureus* PBP2a (PDB ID: 4DKI) (Lovering et al., 2012). The research scheme is shown in Fig. 2.





Collection of molecular descriptors

Eight compounds were derived from curcumin transformation (Fig. 3) that have been synthesized and tested for their antibacterial activities against *S. aureus* (Hamed et al., 2013). It was drawn in 2D and

3D using the ChemBiodraw application. These eight compounds have been successfully synthesized and *in vitro* antibacterial activities in previous research (Hamed et al., 2013). The QSAR equation obtained from pMIC that has been obtained from the antibacte-

rial against *S. aureus* is equated with various descriptors obtained from the ChemBiodraw and pkCSM applications. Descriptors used represent several Hansch QSAR parameters, which are grouped based on three parameters: hydrophobic, electronic, and steric (Hansch and Fujita, 1964; Jhanwar et al., 2011; Kubinyi, 1993).

Multivariate analysis and validation of the QSAR equation

The search for the best equation model used variables depending on the growth inhibition activity of *S. aureus* (log 1/MIC or -log MIC or pMIC) from the results of the previous experiments (Hamed et al., 2013). Independent variables were used in the form of descriptor values representing three parameters: lipophilic, electronic, and steric. All variables were analyzed using the MLR method by initial screening by applying the Pearson correlation or Matrix correlation method using SPSS software. The results obtained were in the form of QSAR equations and statistical parameter values such as the values of *r*, *R*², and *F* (Putra et al., 2023).

The value of *F* indicated the significance of the relationship when compared to the *F* table. The value of *F* was an indicator of the number to show that the relationship, expressed by the obtained equation, was true and not a coincidence. The value of *r* (correlation coefficient) indicated the level of relationship between the biological activity data of experimental observations and the data of calculation results based on equations obtained from regression analysis. A greater value of *r* counts than the *r* table showed a stronger relationship between the biological activity data and experimental observations. The value of *R*² (coefficient of determination) indicated the percentage of biological activity that can be explained in relation to the parameters of physical-chemical properties or descriptors used. A greater value of *R*² counted than the *R*² table showed a strong percentage relationship of biological activity with the descriptor used.

To obtain the model with the highest *r* value, the elimination of the compound that had the greatest deviation based on the value of *Z* in the computation results was conducted, where the structure of the compound with a value of *Z* >2 was eliminated from the statistical calculation. In addition to these statistical parameters, the calculation results also obtained the constant and coefficient values of each independent variable involved in the resulting equation. The obtained coefficient value was used to calculate the activity of theoretical inhibition.

The best QSAR equation was validated with several parameters. There were Fischer criteria (*F*), coef-

ficient of determination (*R*²) >0.6, cross-validation coefficient or leave one out (*Q*²) >0.5, and difference between *R*² and *Q*² ≤0.3 (Adeniji et al., 2018; Chirico and Gramatica, 2011; Gramatica 2007; Putra et al., 2023). These parameters were calculated based on the following formulas [1] and [2].

$$R^2 = 1 - \left[\frac{\sum (Y_{exp} - Y_{Pred})^2}{\sum (Y_{exp} - \bar{Y}_{training})^2} \right] \quad [1]$$

$$Q^2 = 1 - \left[\frac{\sum (Y_{pred} - Y_{exp})^2}{\sum (Y_{exp} - \bar{Y}_{training})^2} \right] \quad [2]$$

Where *Y*_{exp}, *Y*_{pred}, and *Y*_{training} are experimental activity, the predicted activity, and the mean experimental activity of the samples in the training set, respectively.

New models of chemical structure

The best QSAR equation obtained was used to find a better compound candidate by taking into account the pMIC_{pred} value. Molecular docking analysis was redone, ADMET prediction using MVD along with pkCSM online as a feasibility screening process to be synthesized was conducted, and *in vitro* test was also redone on some compound candidates.

In the molecular docking study, we used the software Molegro Virtual Docker (MVD) Ver. 5 with PBP2a receptor as the main target, which was downloaded from the data bank on the website <https://www.rcsb.org/> with the PDB ID: 4DKI (Lovering et al., 2012). The PBP2a structure was obtained through X-ray diffraction from receptor isolates found in *Staphylococcus aureus* subsp. *aureus* COL (Lovering et al., 2012). The validation process involved redocking the native ligand, ceftobiprole, which is a clinically commonly used standard drug in lung cancer cases. The acceptance criterion for the validation process was an RMSD value of <2 Å (Putra et al., 2016; Thomsen and Christensen, 2006).

The new compound design was created using the 2D drawing feature in ChemBiodraw version 11 software. The 2D chemical structure was then converted into a 3D ligand using ChemBio3D version 9 software. The 3D chemical structure underwent a minimal energy calculation using the MMFF94 calculation method, and the ligand was saved as a PDB file (Thomas, 1996). This file was then imported into the MVD application to obtain rerank scores, which represent the free energy of interaction between the ligand and the receptor (Putra et al., 2016; Thomsen and Christensen, 2006). To predict the pharmacokinetic profile data, the compound design file was entered into the online SCF Bio application (<http://www.scfbio-uitd.res.in/software/drugdesign/lipinski.jsp>) to obtain predicted values for the Lipinski rule and pkCSM

(<https://biosig.lab.uq.edu.au/pkcsim/prediction>), and also SIB online (<http://www.swissadme.ch/index.php>) to obtain data on absorption, distribution, metabolism, excretion, and toxicity predictions, the file was submitted to an application that could provide such data (Daina et al., 2017; Jayaram et al., 2013; Pires et al., 2015; Suhud et al., 2019).

RESULTS

Descriptor identification results of curcumin and eight curcumin transformation derivatives

The descriptor used represented several Hansch QSAR parameters, consisting of three parameters: hydrophobic, electronic, and steric (Jhanwar et al., 2011; Kubinyi, 1993; Putra et al., 2023; Todeschini and Consonni, 2009). Lipophilic parameters were Log P, Clog P, and Log S; electronic parameters were TPSA, EHOMO, ELUMO; while steric parameters were molar refractivity (MR), molecular weight (Mr), and molecular volume (MV). The descriptor results of lipophilic, electronic, and steric parameters are shown in Table 1.

Results of multivariate analysis and QSAR equation validation

To obtain the best correlation between pMIC (Y axis) and several descriptors (X axis), screening was used applying the Pearson correlation or Matrix correlation method, which was then carried out by MLR

(Putra et al., 2023; Soni et al., 2009; Verma et al., 2017). The Pearson correlation or Matrix correlation results can be seen in Table 2. Descriptors with a meaningful relationship with pMIC can be seen from results close to 1 or -1. The descriptors included in the QSAR equation were only one because the number of compounds made from this equation is only n = 9. One descriptor parameter can enter the QSAR equation with the number n = 5 (Topliss and Costello, 1972). From the Matrix correlation table results, which still meet the requirements, the electronic parameter is represented by EHOMO with a value of 0.884.

The QSAR equation of screening matrix correlation is created and compared with several other QSAR equations for the MLR process. MLR process was carried out by analyzing the Fischer criteria (F), coefficient of determination (R²), and cross-validation coefficient by leaving one out (Q²) with the results in Table 3.

Based on MLR analysis of four QSAR equations, only QSAR equation [1] met the requirements of the validation criteria. These were a coefficient of determination (R²) >0.6, a cross-validation coefficient or leave one out (Q²) >0.5, and a difference between R² and Q² ≤ 0.3 (Putra et al., 2023). The best QSAR equation was equation 1, pMIC = 0.812 (± 0.162) EHOMO + 5.443 (± 1.659) with sig, r, R², F and Q² values that have met the requirements criteria (Adeniji et al., 2018; Chirico and Gramatica, 2011; Hardjono et al., 2016, Luo et al., 2012; Putra et al., 2023). The Z score between pIC₅₀ experimental and pIC₅₀ prediction was also nothing more than 2, which can be seen in Table 4 and Fig. 3.

Table 1. Descriptors of lipophilic, electronic and steric parameters of curcumin and its transformation derivatives.

Compound	Y axis	X axis								
	pMIC	Lipophilic			Electronic			Steric		
		Log P	ClogP	Log S	TPSA	EHOMO	ELUMO	MR	Mr	MV
Curcumin	-3.988	3.15	2.25	-4.20	93.06	-11.03	-5.29	102.80	368.38	156.53
1	-3.280	5.21	5.94	-6.91	76.74	-10.61	-3.03	131.33	440.49	191.84
2	-3.225	5.02	5.68	-7.70	168.38	-10.54	-4.02	148.98	530.49	221.14
3	-2.685	4.60	4.87	-6.56	89.63	-9.68	-3.14	129.13	441.48	191.06
4	-2.687	4.50	5.92	-5.93	106.95	-10.81	-4.74	128.43	458.46	195.16
5	-2.726	2.65	2.77	-4.82	131.86	-10.41	-2.91	117.36	422.43	178.17
6	-3.380	4.01	3.87	-5.12	84.95	-10.92	-3.59	104.27	365.38	156.14
7	-1.169	3.54	3.63	-4.56	83.64	-8.47	-2.35	128.73	406.47	176.09
8	-2.629	6.14	6.28	-6.84	83.31	-9.44	-3.43	146.87	478.62	208.88

TPSA: total polarity surface area; RS: rerank score; MR: molar refractivity; Mr: molecular weight; Mv: molecular volume.

Table 2. Person correlation or Matrix correlation of PIC₅₀ with its various descriptors.

Descriptor	pMIC	Log P	ClogP	LogS	TPSA	EHOMO	ELUMO	MR	Mr	MV
pMIC	1									
Log P	-0.028	1								
ClogP	0.091	0.924	1							
LogS	0.109	0.852	-0.880	1						
TPSA	-0.147	-0.124	0.016	-0.304	1					
EHOMO	0.884	0.136	0.086	0.013	-0.265	1				
ELUMO	0.682	0.036	0.064	-0.076	-0.197	0.695	1			
MR	0.358	0.750	0.797	-0.823	0.321	0.433	0.267	1		
Mr	0.121	0.655	0.756	-0.862	0.587	0.131	0.038	0.930	1	
MV	0.172	0.727	0.812	-0.884	0.470	0.207	0.100	0.963	0.990	1

Table 3. Multiple linear regression of QSAR equations.

Equation number/name	QSAR equation					
(1) EHOMO	pMIC = 0.812 (± 0.162) EHOMO + 5.443 (± 1.659)					
	n = 9	Sig = 0.002	r = 0.884	R ² = 0.782	F = 25.153	Q ² = 0.57
(2) ELUMO	pMIC = 0.570 (± 0.231) ELUMO - 0.805 (± 0.859)					
	n = 9	Sig = 0.043	r = 0.682	R ² = 0.465	F = 6.080	Q ² = -0.02
(3) Log S	pMIC = 0.069 Log S (± 0.239) -2.458 (± 1.422)					
	n = 9	Sig = 0.780	r = 0.109	R ² = 0.012	F = 0.084	Q ² = -3.36
(4) MR	pMIC = 0.017 MR (± 0.017) -5.039 (± 2.159)					
	n = 9	Sig = 0.344	r = 0.358	R ² = 0.128	F = 1.030	Q ² = -0.43

Table 4. Difference of pIC₅₀ experimental and pIC₅₀ prediction.

Compound	pIC ₅₀ Experimental	pIC ₅₀ Prediction	Residues (Z score)
Curcumin	-3.988	-3.526	0.462
1	-3.280	-3.186	0.094
2	-3.225	-3.125	0.100
3	-2.685	-2.428	0.257
4	-2.687	-3.346	-0.659
5	-2.726	-3.017	-0.290
6	-3.380	-3.437	-0.058
7	-1.169	-1.448	-0.279
8	-2.629	-2.234	0.395

Determination of new compound design

From the QSAR equation, to obtain a more potent compound with a lower IC₅₀ or a greater pMIC value, it is necessary to design a compound with criteria greater than EHOMO than compound 7. This means that to increase the value of the EHOMO/energy

highest occupied molecular orbital, reducing the number of conjugated double bonds is advisable.

Compound 7 with experimental pMIC values and the largest prediction pMIC are used as reference standards to find candidates for more potent compounds. From the analysis of the EHOMO criteria, we would get a new compound design. Those were three










Table 5. Descriptor and pIC₅₀ prediction of new model chemicals structure.

Compound	EHOMO	pMIC prediction
<div></div> <div>Curcumin</div>	-11.03	-3.988
<div></div> <div>Compound 7</div>	-8.47	-1.445
<div></div> <div>New 1</div>	-7.98	-1.047
<div></div> <div>New 2</div>	-8.17	-1.201
<div></div> <div>New 3</div>	-8.19	-1.217

candidate compounds suitable for re-synthesizing, which were code-named New 1-3. The EHOMO results of compound 4 and New 1-3 compounds can be seen in Table 5.



Molecular docking study and ADMET prediction of new compound design

New 1-3 were prepared as ligands by drawing them in two dimensions in ChembiDraw version 11 software. The 2-dimensional ligand was then converted into the 3-dimensional ligand in ChemBio3D version 11 software. The 3-D ligand performs the most stable minimal energy calculation by means of the MMFF94 calculation, and the ligand is stored in the PDB file type. (Thomas, 1996).

The receptors *S. aureus* PBP2a (PDB ID: 4DKI) were obtained from the Protein Data Bank (PDB) with PDB ID: 4DKI, which was re-prepared with Molegro Virtual Docker (MVD) Ver.5.5 (Lovering et al., 2012). PBP2a and its comparison ligand ceftobiprole were re-docked to validate the Molegro Virtual Docker (MVD) Ver.5.5. Therefore, it was used to dock the New 1-3 compounds.

Redocking aims to validate the downloaded PDB files and the software used for the New 1-3 compounds docking method to obtain valid and correct results. The redocking acceptance parameter is the root mean square deviation (RMSD) value <2.0 Å.

The grid box binding site was set $X = 29.35$ Å; $Y = 30.01$ Å; $Z = 86.82$ Å with a cavity surrounded by 27 amino acids. They were Gly 402, Ser 403, Lys 406, Lys 430, Tyr 446, Glu 447, Glu 460, Ser 462, Asp 463, Asn 464, Tyr 519, Gly 520, Gln 521, Lys 581, His 583, Asp 586, Lys 597, Ser 598, Gly 599, Thr 600, Ala 601, Glu 602, Met 605, Met 641, Ala 642, Ser 643, and Lys 647. The result of the redocking validation process with RMSD 1.19 Å is shown in Fig. 4. Hence, these results indicate that the method is valid for the docking test of the tested compound since the RMSD obtained is less than 2 Å (Sulistiyowaty et al., 2023). The RMSD value showed the compatibility of the ligand coordinates from the crystallographic results compared to the ligand coordinates, which was redocked ceftobi-

prole on PBP2a of 1.19 Å, which is in accordance with the criteria of the docking process (Fig. 4).


Based on the docking result, a rerank score was obtained and interpreted as the prediction of the bond interaction between the drug and the receptor. The smaller the rerank score, the greater the degree of compatibility between the ligand and the receptor. The docking results can also be visualized and interpreted to provide an overview of the interaction of ligand bonds with receptors, including hydrogen bond interactions, hydrophobic interactions, and electronic interactions (Table 6 and Fig. 5).

The result of the rerank score of New 1-3 compounds proved to be lower than its native ligand, ceftobiprole (-69.74 kcal/mol), and reference drug standard for MRSA, methicillin (-79.31 kcal/mol). Based on the value of the rerank score, if it were arranged from the lowest to the highest energy, a rerank score was obtained as follows: New1 < New2 < New3 < methicillin < ceftobiprole. The presence of unconjugated ring such as cyclopentane at chemical structure New 1 caused higher EHOMO and made it a suitable interaction with PBP2a than chemical structure New 2 and New 3.

Based on the results of ADMET prediction using SCFbio software, New 1-3 compounds adhere to Lipinski's Rule of Five criteria, which encompass Log $P < 5$; Hydrogen Bond Donors (HBD) ≤ 5 ; Hydrogen Bond Acceptor (HBA) ≤ 5 ; MR 40-130 Å; Mr ≤ 500 . Therefore, based on this prediction, these were predicted that New 1-3 compounds would be absorbed through the gastrointestinal tract (GIT) (Jayaram et al., 2013; Sulistiyowaty et al., 2021). However, absorption predictions based on Lipinski's rule of five for ceftobiprole and methicillin fall outside of the criteria. As a result, ceftobiprole and methicillin are not formulated for clinical use in oral dosage forms, and both are only available in intravenous (IV) injection

Table 6. The Molecular docking result of ceftrobiprole, methicillin, compound 7, and New 1-3 compounds into active site *Staphylococcus aureus* penicillin-binding protein 2a.

Compound	Rerank score (kcal/mol)	Hydrogen bond	Steric interaction	Electronic interaction
Ceftobiprole	-69.74	Ser 403; Lys 406; Ser 462; Tyr 519; Ln 521; Ser 598; Thr 600; Ala 601	Ser 403; Lys 406; Ser 462; Tyr 446; Asn 464; Tyr 519; Gly 520; Gly 521; Ser 598; Gly 599; Thr 600; Ala 601; Glu 602	Lys 597
Methicillin	-79.31	Ser 403; Lys 406; Ser 462; Asn 464; Gly 521; Thr 600	Gly 402; Ser 403; Lys 406; Ser 462; Asn 464; Tyr 519; Gln 521; Thr 600	Lys 597
Compound 7	-102.50	Ser 403; Ser 462; Asn 464; Thr 600; Glu 602	Ser 403; Tyr 446; Ser 461; Ser 462; Asn 464; Thr 600; Glu 602; Gly 613	-
New 1	-125.81	Ser 400; Glu 447	Glu 402; Glu 447; Ser 461; Asn 464; Tyr 519; Ala 601	-
New 2	-116.99	Ser 403; Glu 447; Thr 600; Ile 614	Gly 402; Ser 403; Glu 447; Ser 461; Asn 464; Gln 521; Gly 599; Thr 600; Ala 601; Ile 614; Trp 616	-
New 3	-107.77	Ser 403; Glu 447; Ser 461; Asn 464; Thr 600; Ala 642; Ser 643	Ser 403; Tyr 446; Glu 447; Ser 461; Ser 462; Asn 464; Gln 521; Ser 598; Thr 600; Met 641; Ala 642; Ser 643	



formulations. Both indeed exhibit poor absorption in the GIT. In fact, of that, methicillin is not clinically used due to its high polarity, leading to significant nephrotoxic side effects.

New 1-3 compounds absorption prediction based on the Caco2 permeability value of New 1-3 compounds were better than ceftobiprole and methicillin. Caco2 cell lines are human epithelial colorectal adenocarcinoma cells that are cell monolayers often used as human intestinal mucosa models *in vitro* for permeability prediction for peroral drug absorption. Compounds are categorized as having high permeability if the Caco2 permeability value is $>8.10^{-6}$ cm/s (Pires et al., 2015). In addition to permeability parameters, water solubility parameters also play a crucial role in predicting absorption in the GIT. New 1-3 compounds have log S values ranging from -6.40 to -5.24, including in the moderately soluble category. In contrast, ceftobiprole has a log S value of -2.91, and methicillin has a log S value of -3.05, both classified as soluble. Based on the Biopharmaceutical Classification System (BCS), New 1-3 compounds could be included in BCS class II, with low permeability and high solubility characteristics. Therefore, the percentage of human intestinal absorption is classified as great or very good ($>80\%$). Meanwhile, ceftobiprole and methicillin have a human intestinal absorption percentage of 24-45%, which was included in the poor-moderate absorption category. This is because both do not meet Lipinski's rule of five criteria and show lower permeability than New 1-3 compounds (Daina et al., 2017; Pires et al., 2015; Suhud et al., 2019).

The distribution prediction is based on the value of the blood-brain barrier (BBB) permeability of ceftobiprole and methicillin, and the New 1-3 compounds are estimated not to penetrate BBB. BBB is a protective monolayer of the brain, so chemical compounds cannot easily be entered into nerve cells. Drugs are divided to be categorized as readily cross BBB if the log BB value is >0.3 . Ceftobiprole, methicillin, and New 1-3 compounds have a log BB value <0.3 (Pires et al., 2015). This is already expected because the compounds that can penetrate the BBB can certainly affect the central nervous system (CNS) and patient awareness. Several drugs are designed to penetrate the BBB, such as antibiotics for cases of meningitis infection, drugs for Parkinson's, and drugs for general anesthesia. These drugs are designed for MRSA infection so that it is not expected to penetrate the BBB (Trevor et al., 2015).

Cytochrome 450 (CYP) is an important detoxification enzyme found in the body and is widely found in the liver (Shargel et al., 2016; Trevor et al., 2015). The

CYP enzymes activate and deactivate many drugs. Therefore, predicting the drug compounds, including whether or not they inhibit CYP, is very important. Some isoforms of the CYP are CYP 2D6 and 3A4. Both isoforms are drug metabolizers of almost $>90\%$. This metabolism prediction is essential for screening whether the new compounds will most likely interact with other drugs in the metabolic phase. Ceftobiprole and methicillin are the standard drugs used for MRSA bacteria at *in vitro* assay. Both do not inhibit CYP 2D6 and CYP 3A4. Therefore, there are not many interactions with other drugs. Some drugs that are predicted to increase drug levels in the blood (bioavailability) due to the presence of CYP 3A4 inhibitors are antiarrhythmic drugs, antidepressants,azole antifungals, benzodiazepines, calcium channel blockers, cyclosporine, delavirdine, doxorubicin, efavirenz, erythromycin, estrogen, HIV protease inhibitors, nefazodone, paclitaxel, proton pump inhibitors, HMG-CoA reductase inhibitors, rifabutin, rifampicin, sildenafil, SSRIs, tamoxifen, trazodone, and vinca alkaloids (Trevor et al., 2015). Predicted metabolism of New 1-3 compounds did not inhibit the CYP 2D6 enzyme. However, New 1-3 compounds inhibited the CYP 3A4 enzyme.

New 1-3 compounds were predicted to be inhibitory for CYP 2C9 and CYP 2C19. Even though these two cytochromes metabolize drugs not as much as CYP 3A4, they still have to be careful because several drugs are predicted to increase drug levels in the blood (bioavailability) as a result of the presence of CYP 2C9 inhibitors, such as barbiturates, celecoxib, chloramphenicol, doxorubicin, ibuprofen, phenytoin, chlorpromazine, steroids, tolbutamide, and (S)-warfarin (Trevor et al., 2015). Meanwhile, several drugs are thought to increase drug levels in the blood (bioavailability) due to CYP2C9 inhibitors, for example, diazepam, phenytoin, topiramate, (R)-warfarin (Trevor et al., 2015).

The prediction of toxicity of New 1-3 compounds is that they are not hepatotoxic, while ceftobiprole and methicillin are hepatotoxic. The LD₅₀ prediction also showed that New 1 was safer than others, with a value of LD₅₀ = 2.709 mol/kg.

Overall, the results of pharmacokinetic prediction or ADMET prediction of New 1-3 compounds using pkCSM software and SIB online can be seen in Table 7.

From the QSAR and ADMET predictions, New 1 is predicted to have the most potential IC₅₀ against MRSA bacteria and more safety than others because New 1 has the greatest LD₅₀ for oral rat acute toxicity prediction and non-hepatotoxic. However, it is still

Table 7. The result of ADMET predictions.

Compound	Absorption			Distribution		Metabolism (CYP inhibitor)				Excretion	Toxicity	
	Caco2 Perm. 10 ⁻⁶ cm/s	Log S	HIA (%)	BBB Perm. (BB log)	2D6	3A4	2C9	2C19	Total clearance log mL/min/kg		Oral rat acute toxicity mol/kg (LD ₅₀)	Hepato toxicity
New 1	4.27	-5.65	89.71	-0.43	No	Yes	Yes	Yes	0.986		2.709	No
New 2	4.57	-5.24	89.98	-0.45	No	Yes	Yes	Yes	0.361		2.524	No
New 3	5.01	-6.40	100	-0.89	No	Yes	Yes	Yes	-0.081		2.559	No
Ceftobiprole	0.36	-2.91	24.09	-1.84	No	No	No	No	0.233		2.245	Yes
Methicillin	3.63	-3.05	45.34	-1.29	No	No	No	No	0.383		1.861	Yes

Perm: permeability; HIA: human intestinal absorption BBB: blood-brain barrier; CYP: cytochrome P450.

predicted to have more drug interaction than methicillin because New 1 was predicted as a CYP 3A4 inhibitor.

CONCLUSION

The best QSAR equation is pMIC = 0.812 (± 0.162) EHOMO + 5.443 (± 1.659), and the New 1 compound is the main candidate to be synthesized because it is very potential and has a better toxicity prediction than methicillin and ceftobiprole so that it can be tested on MRSA bacteria to prove the results of IC₅₀ prediction.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

ACKNOWLEDGMENTS

This research was partially funded by Universitas Negeri Malang (Faculty Decentralization Scheme) in the grant year 2023 (No: 3.4.93/UN32/KP/2024).

REFERENCES

Adeniji SE, Uba S, Uzairu A (2018) QSAR modeling and molecular docking analysis of some active compounds against *Mycobacterium tuberculosis* receptor (Mtb CYP121). *J Pathog* 2018: 1018694. <https://doi.org/10.1155/2018/1018694>

Boehlich GJ, de Vries J, Geismar O, Gudzuhn M, Streit WR, Wicha SG, Schützenmeister N (2020) Total synthesis of anti-MRSA active diorcinols and analogues. *Chemistry*. 26(44): 9846-9850. <https://doi.org/doi:10.1002/chem.202002442>

Chirico N, Gramatica P (2011) Real external predictivity of QSAR models: How to evaluate it? Comparison of different validation criteria and proposal of using the concordance correlation coefficient. *J Chem Inf Model* 51: 2320-2335. <http://doi.org/10.1021/ci200211n>

Daina A, Michielin O, Zoete V (2017) SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci Rep* 7: 42717. <https://doi.org/10.1038/srep42717>

Gordon ON, Luis PB, Sintim HO, Schneider C (2015) Unraveling curcumin degradation: Autoxidation proceeds through spiroepoxide and vinyl ether intermediates en route to the

main bicyclopentadione. *J Biol Chem* 290(8): 4817-4828. <https://doi.org/10.1074/jbc.M114.618785>

Gramatica P (2007) Principles of QSAR models validation: Internal and external. *QSAR Comb Sci* 2(5): 694-701. <https://doi.org/10.1002/qsar.200610151>

Green BN, Johnson CD, Egan JT, Rosenthal M, Griffith EA, Evans MW (2012) Methicillin-resistant *Staphylococcus aureus*: An overview for manual therapists. *J Chiropr Med* 11(1): 64-76. <https://doi.org/doi:10.1016/j.jcm.2011.12.001>

Hamed OA, Mehdawi N, Taha AA, Hamed EM, Al-Nuri MA, Hussein AS (2013) Synthesis and antibacterial activity of novel curcumin derivatives containing heterocyclic moiety. *Iran J Pharm Res* 12(1): 47-56. <http://www.ncbi.nlm.nih.gov/pmc/articles/pmc3813224/>

Hansch C, Fujita T (1964) ρ-σ-π Analysis. A method for the correlation of biological activity and chemical structure. *J Am Chem Soc* 86: 1616-1626. <https://doi.org/10.1021/ja01062a035>

Hardjono S, Siswodihardjo S, Pramono P, Darmanto W (2016) Quantitative structure-cytotoxic activity relationship 1-(benzoyloxy)urea and its derivative. *Curr Drug Discov Technol* 13(2): 101-108. <https://doi.org/10.2174/1570163813666160525112327>

Jayaram B, Tanya S, Goutam M, Abhinav M, Shashank S, Sanjeevini VS (2013) A freely accessible web-server for target directed lead molecule discovery. *BMC Bioinf* 13(Suppl 17): S7. <https://doi.org/10.1186/1471-2105-13-S17-S7>

Jhanwar B, Sharma V, Singla RK, Shrivastava B (2011) QSAR-Hansch analysis and related approaches in drug design. *Pharmacologyonline* 1: 306-344.

Kubinyi H (1993) QSAR-Hansch analysis and related approaches. In *Methods and Principles in Medicinal Chemistry*. Vol. I. New York: VCH Verlagsgesellschaft. <https://doi.org/10.1002/9783527616824>

Larsen J, Raisen CL, Ba X, Sadgrove NJ, Padilla-González GF, Simmonds MSJ, Loncaric I, Kerschner H, Apfalter P, Hartl R, Deplano A, Vandendriessche S, Bolfíková BC, Hulva P, Arendrup M (2022) Emergence of methicillin resistance predates the clinical use of antibiotics. *Nature* 602: 135-141. <https://doi.org/10.1038/s41586-021-04265-w>

Lovering AL, Gretes MC, Safadi SS, Danel F, de Castro L, Page MG, Strynadka NCJ (2012) Structural insights into the anti-methicillin-resistant *Staphylococcus aureus* (MRSA) activity of ceftobiprole. *J Biol Chem* 287(38): 32096-32102. <https://doi.org/doi:10.1074/jbc.m112.355644>

Luo X, Shu M, Wang Y, Liu J, Yang W, Lin Z (2012) 3D-QSAR studies of dihydropyrazole and dihydropyrrole derivatives as inhibitors of human mitotic kinesin Eg5 based on molecular docking. *Molecules* 17(2): 2015-2029. <https://doi.org/10.3390/molecules17022015>

Masumi M, Noormohammadi F, Kianisaba F, Nouri F, Taheri M, Taherkhani A (2022) Methicillin-resistant *Staphylococcus aureus*: docking-based virtual screening and molecular dynamics simulations to identify potential penicillin-binding protein 2a inhibitors from natural flavonoids. *Int J Microbiol* 2022: 9130700. <https://doi.org/10.1155/2022/9130700>

Mun SH, Kim SB, Kong R, Choi JG, Kim YC, Shin DW, Kang OH, Kwon DY (2014) Curcumin reverse methicillin resistance in *Staphylococcus aureus*. *Molecules*. 19(11): 18283–18295. <https://doi.org/10.3390/molecules191118283>

Pires DEV, Blundell TL, Ascher DB (2015) pkCSM: Predicting small molecule pharmacokinetic and toxicity properties using graph based signatures. *J Med Chem*. 58(9): 4066–4072. <https://doi.org/10.1021/acs.jmedchem.5b00104>

Putra GS, Sulistyowaty MI, Yuniarta TA, Yahmin Y, Sumari S, Saechan C, Yamauchi T (2023) QSAR study of benzylidene hydrazine benzamides derivatives with *in-vitro* anticancer activity against human lung cancer cell line A459. *J Pharm Pharmacogn Res* 11(6): 1123–1136. <https://doi.org/10.56499/jppres23.1718.11.6.1123>

Putra GS, Yuniarta TA, Syahrani A, Rudyanto M (2016) Synthesis, molecular docking study and brine shrimp lethality test of benzoxazine and aminomethyl derivatives from eugenol. *Int J Pharm Sci Rev Res* 5(4): 1–11.

Schneider C, Gordon ON, Edwards RL, Luis PB (2015) Degradation of curcumin: From mechanism to biological implications. *J Agric Food Chem* 63(35): 7606–7614. <https://doi.org/10.1021/acs.jafc.5b00244>

Schraufstatter E, Bernt H (1949) Antibacterial action of curcumin and related compounds. *Nature* 164(4167): 456–457. <https://doi.org/10.1038/164456a0>

Shargel L, Yu ABC (2016) Applied Biopharmaceutics & Pharmacokinetics, 7th ed. New York: The McGraw-Hill Companies. 928 pages.

Soni LK, Gupta AK, Kaskhedikar SG (2009) Exploration of QSAR modelling techniques and their combination to rationalize the physicochemical characters of nitrophenyl derivatives towards aldose reductase inhibition. *J Enzyme Inhib Med Chem* 24(4): 1002–1007. <https://doi.org/10.1080/14756360802565486>

Suhud F, Tjahjono DH, Yuniarta TA, Putra GS, Setiawan J (2019) Molecular docking, drug-likeness, and ADMET study of 1-benzyl-3-benzoylurea and its analogs against VEGFR-2. *IOP Conf Ser: Earth Environ Sci* 293: 012018. <https://doi.org/doi:10.1088/1755-1315/293/1/012018>

Sulistyowaty MI, Putra GS, Budiati T, Indrianingsih AW, Anwari F, Kesuma D, Matsunami K, Yamauchi T (2023) Synthesis, *in silico* study, antibacterial and antifungal activities of n-phenylbenzamides. *Int J Mol Sci* 24(3): 2745. <https://doi.org/10.3390/ijms24032745>

Sulistyowaty MI, Widyowati R, Putra GS, Budiati T, Matsunami K (2021) Synthesis, ADMET predictions, molecular docking studies, and *in-vitro* anticancer activity of some benzoxazines against A549 human lung cancer cells. *J Basic Clin Physiol Pharmacol* 32(4): 385–392. <https://doi.org/10.1515/jbcpp-2020-0433>

Teow SY, Liew K, Ali SA, Khoo ASB, Peh SC (2016) Antibacterial action of curcumin against *Staphylococcus aureus*: A brief review. *J Trop Med* 2016: 2853045. <https://doi.org/10.1155/2016/2853045>

Thomas HA (1996) Merck Molecular Force Field. I. Basis, form, scope, parametrization, and performance of MMFF94. *J Com Chem* 17(5-6): 490–519. [https://doi.org/10.1002/\(SICI\)1096-987X\(199604\)17:5/6%3C490::AID-JCC1%3E3.0.CO;2-P](https://doi.org/10.1002/(SICI)1096-987X(199604)17:5/6%3C490::AID-JCC1%3E3.0.CO;2-P)

Thomsen R, Christensen MH (2006) MolDock: A new technique for high-accuracy molecular docking. *J Med Chem* 49(11): 3315–3321. <https://doi.org/10.1021/jm051197e>

Todeschini R, Consonni V (2009) Molecular Descriptors for Chemoinformatics. Volume I & II. In: *Methods and Principles in Medicinal Chemistry* (Series Nr. 41). Weinheim: Wiley-VCH Verlag. 1220 Pages.

Topliss JG, Costello RJ (1972) Chance correlations in structure-activity studies using multiple regression analysis. *J Med Chem* 15(10): 1066–1068. <https://doi.org/10.1021/jm00280a017>

Trevor AJ, Katzung BG, Kruidering-Hall M (2015) Katzung and Trevor's. *Pharmacology Examination & Board Review*, 11th ed. New York: The McGraw-Hill Education. 592 pages.

Verma V, Singh K, Kumar D, Narasimhan B (2017) QSAR studies of antimicrobial activity of 1,3-disubstituted-1H-naphtho[1,2-e][1,3]oxazines using topological descriptors. *Arab J Chem* 10(1): S747–S756. <https://doi.org/10.1016/j.arabjc.2012.11.021>

Zhang ZS, Huang YZ, Luo J, Wang BF, Jin Z, Liu YH, Tang YZ (2018) Synthesis and antibacterial activity against MRSA of pleuromutilin derivatives Possessing a mercaptoethylamine linker. *Med Chem* 14(6): 585–594. <https://doi.org/doi:10.2174/1573406414666180416131737>

AUTHOR CONTRIBUTION:

Contribution	Kesuma D	Putra GS	Yahmin Y	Sumari S	Putri AO	Anwari F	Salmasfatah N	Sulistyowaty MI
Concepts or ideas	x	x	x		x	x		
Design		x		x	x	x		
Definition of intellectual content		x		x	x	x		
Literature search	x	x	x	x	x	x	x	x
Experimental studies			x	x				x
Data acquisition	x	x		x	x			
Data analysis		x	x	x	x			
Statistical analysis		x		x			x	
Manuscript preparation			x				x	
Manuscript editing	x	x	x				x	x
Manuscript review	x	x	x	x	x	x	x	x

Citation Format: Kesuma D, Putra GS, Yahmin Y, Sumari S, Putri AO, Anwari F, Salmasfatah N, Sulistyowaty MI (2024) Hansch analysis by QSAR model of curcumin and eight of its transformed derivatives with antimicrobial activity against *Staphylococcus aureus*. J Pharm Pharmacogn Res 12(5): 1008–1020. https://doi.org/10.56499/jppres24.1945_12.5.1008

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Open Access: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Journal of Pharmacy & Pharmacognosy Research



JPPRes

Journal of Pharmacy
& Pharmacognosy
Research



Editorial Board



JPPRes

Journal of Pharmacy
& Pharmacognosy
Research

Gabino Garrido

Editor-in-Chief

[Scholar Google](#)

[Scopus](#)

[ResearchGate](#)

[ORCHID](#)

GarVal Editorial Ltda.

[Email](#)

Marisela Valdés González

Executive Editor

[ORCID](#)

GarVal Editorial Ltda.



Editorial and Design Manager

[LinkedIn](#)

[Behance](#)

[Web](#)

AVAGAX Studio

Antofagasta, Chile

[Email](#)

Editorial Board Members



Antonio Vassallo

Dipartimento di Scienze. Università degli Studi della Basilicata, Potenza, Italia.

[Research Gate](#)

[ORCID](#)

[Scopus](#)



Bárbara B. Garrido Suárez

Laboratorio de Farmacología y Toxicología, Centro de Investigación y Desarrollo de
Medicamentos, La Habana, Cuba.



Carla Delporte

Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago,
Chile

[Research Gate](#)

[ORCID](#)



Damaris Silveira

Faculdade de Ciências da Saúde, Universidade de Brasília, Brazil

[Lattes](#)

[ORCID](#)



Douglas S. de Almeida Chaves

Dep. de Ciências Farmacêuticas (DCFAR), Instituto de Ciências Biológicas e da Saúde,
Universidade Federal Rural do Rio de Janeiro, Rodovia, RJ. Brazil

[ResearchGate](#)

[ORCID](#)

[Lattes](#)



Edgar Pastene



Etile Spegazzini

Universidad de Belgrano, Buenos Aires, Argentina

[ResearchGate](#)



Farid Chemat

Université Avignon et des Pays de Vaucluse, Avignon, France

[ResearchGate](#)



Fidel O. Castro

Departamento de Ciencias Pecuarias, Universidad de Concepción, Chillán, Chile

[ResearchGate](#)

[ORCID](#)



Guilherme N. L. do Nascimento

Universidade Federal de Tocantins. Brazil



Jacqueline Sepúlveda

Universidad de Concepción, Concepción, Chile

[ResearchGate](#)

[ORCID](#)



Jelena Nadinic

Universidad de Buenos Aires, Argentina.

[ResearchGate](#)

[ORCID](#)



José H. Isaza-Martínez

Universidad del Valle, Cali, Colombia

[ResearchGate](#)

[ORCID](#)



Juan C. Sepúlveda-Arias

Universidad Tecnológica de Pereira, Pereira, Colombia



Madan Mohan Gupta

School of Pharmacy, Faculty of Medical Sciences. The University of the West Indies,
Trinidad & Tobago, West Indies

[Google Scholar](#)

[ORCID](#)



Mahomoodally M. Fawzi

Department of Health Sciences, Faculty of Science, University of Mauritius. Mauritius.

[ORCID](#)

[ResearchGate](#)



María Inés Isla

Facultad de Ciencias Naturales e Instituto Miguel Lillo. Universidad Nacional de
Tucumán, Tucumán, Argentina.

[ResearchGate](#)

[ORCID](#)



Marisol Fernández Alfonso



Mayank Gangwar

Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi (UP) India

[Scholar Google](#)

[ORCID](#)



Silvia Debenedetti

Pharmacy Career. Universidad de Belgrano, Buenos Aires, Argentina

[ORCID](#)

[ResearchGate](#)



Vikash Kumar Ruhil

PDM College of Pharmacy, Bahadurgarh, Haryana, India

[Google Scholar](#)



Yasser Shahzad



JPPRes

Journal of Pharmacy
& Pharmacognosy
Research



Reviewers

The reviewers will be recruited among researchers and clinicians with high international reputation in Pharmacy and Pharmacognosy.

Last Update: August 20th, 2023



JPPRes

Journal of Pharmacy
& Pharmacognosy
Research

[Home](#) [About](#) [Archive](#) [Authors](#) [Reviewers](#) [Events](#) [Blog](#)



[Twitter](#)



[LinkedIn](#)



[Facebook](#)

© 2013–2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license–Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by **AVAGAX Studio**



Volume 12, Issue 5


J Pharm Pharmacogn Res 12(5), (Sep-Oct) 2024

Journal of
**Pharmacy
& Pharmacognosy Research**




IFC (**Journal of Pharmacy & Pharmacognosy Research**).


1.- Original Article

Lennin R. Rodriguez-Saavedra, Pedro M. Alva-Plasencia, Yuri F. Curo-Vallejos, Segun F. Saavedra-Suárez, Luis A. Chávez-Abanto, Olga E. Caballero-Aquiño, Miriam Gutiérrez-Ramos, Junior F. Sánchez-Bautista (2024) **Dissolution kinetics of propranolol hydrochloride 40 mg tablets under biowaiver conditions.** | [Cinética de disolución de tabletas de propranolol clorhidrato 40 mg en condiciones de bioexención]. J Pharm Pharmacogn Res 12(5): 814-821. https://doi.org/10.56499/jppres23.1853_12.5.814  [426 Kb] [ABSTRACT]


2.- Original Article

Aiyi Asnawi, Ellin Febrina, Widhya Aligita, La Ode Aman, Fachrul Razi (2024) **Molecular docking and molecular dynamics study of 3-hydroxybutyrate with polymers for diabetic ketoacidosis-targeted molecularly imprinted polymers.** | [Estudio de acoplamiento molecular y dinámica molecular de 3-hidroxibutirato con polímeros para polímeros de impresión molecular dirigidos a cetoacidosis diabética]. J Pharm Pharmacogn Res 12(5): 822-836. https://doi.org/10.56499/jppres23.1926_12.5.822  [736 Kb] [ABSTRACT]


3.- Original Article

Irene Natalia Nesta Sihombing, Ade Arsianti (2024) **Network pharmacology prediction and molecular docking analysis on the mechanism of eugenol as a candidate against estrogen receptor-positive breast cancer.** | [Predicción farmacológica en red y análisis de acoplamiento molecular sobre el mecanismo del eugenol con candidato contra el cáncer de mama con receptores de estrógeno positivos]. J Pharm Pharmacogn Res 12(5): 837–851. https://doi.org/10.56499/jppres23.1699_12.5.837  [1.17 Mb] [ABSTRACT]


4.- Review

Alisson A. de Oliveira, Celso B. dos Santos, Luiz A. Pilatti (2024) **Bridging the gap patent assessment: The Index of Internal Effort framework for pharma innovations** [Salvando las distancias en la evaluación de patentes: El marco del Índice de Esfuerzo Interno para las innovaciones farmacéuticas]. J Pharm Pharmacogn Res 12(5): 852–869. https://doi.org/10.56499/jppres23.1859_12.5.852  [672 Kb] [ABSTRACT]

5.- Original Article


Poppy Anjelisa Zaitun Hasibuan, Jane Melita Keliat, Muhammad Fauzan Lubis (2024) **Combination of cisplatin and ethyl acetate extract of *Vernonia amygdalina* Delile induces cell cycle arrest and apoptosis on PANC-1 cells via PI3K/mTOR.** [Combinación de cisplatino y extracto de acetato de etilo de *Vernonia amygdalina* Delile induce la detención del ciclo celular y la apoptosis en células PANC-1 vía PI3K/mTOR]. J Pharm Pharmacogn Res 12(5): 870–880. https://doi.org/10.56499/jppres23.1748_12.5.870  [695 Kb] [ABSTRACT]

6.- Original Article


Precella Silvia, Jeremi Ongko, Yulanda Antonius (2024) **Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from *Calophyllum inophyllum* L. leaves as potential non-small cell lung cancer drugs.** | [Inhibidor del receptor del factor de crecimiento epidérmico mutante T790M-L858R-V948R de la hoja de *Calophyllum inophyllum* L. como posible fármaco contra el cáncer de pulmón de células pequeñas]. J Pharm Pharmacogn Res 12(5): 881–891. https://doi.org/10.56499/jppres23.1740_12.5.881  [772 Kb] [ABSTRACT]

7.- Original Article


Binh Quoc Pham, Ngan Kim Thi Nguyen, Su Quoc Pham, Cuong Duy Nguyen, Lam Van Trinh, Hang Thu Thi Dinh, Quang Vinh Trinh, Van Anh Thi Pham (2024) **Potential effects of *Linh Loc Son* hard capsule – a Vietnamese herbal combination – on immunodeficiency induced by cyclophosphamide on mice.** | [Efectos potenciales de la cápsula dura *Linh Loc Son*, una combinación de hierbas vietnamitas en inmunodeficiencia inducida por ciclofosfamida en ratones]. J Pharm Pharmacogn Res

12(5): 892–899. https://doi.org/10.56499/jppres23.1751_12.5.892  [485 Kk]
[ABSTRACT]


8.– Original Article

Paween Kunsorn, Witchuda Payuhakrit, Nasapon Povichit, Prasit Suwannalert (2024) **Piceatannol-rich extract from *Passiflora edulis* Sims seeds attenuates morphological differentiation through the reduction of MITF mRNA expression and actin polymerization in UVB-induced hyperpigmented B16F10 cells.** | [El extracto rico en piceatannol de las semillas de *Passiflora edulis* Sims atenúa la diferenciación morfológica mediante la reducción de la expresión de ARNm de MITF y polimerización de F-actina en células B16F10 hiperpigmentadas inducidas por UVB] J Pharm Pharmacogn Res 12(5): 900–910. https://doi.org/10.56499/jppres23.1717_12.5.900  [860 Kb] [ABSTRACT]


9.– Review

Julio C. Romero-Gamboa, Melissa Pinella-Vega, Pablo A. Millones-Gómez, John Gallego-Ramírez, Alejandro Valencia-Arias (2024) **Research trends in the study of biofilms related to periodontal disease: A bibliometric analysis.** | [Tendencias de investigación en el estudio de las biopelículas relacionadas con la enfermedad periodontal: Un análisis bibliométrico]. J Pharm Pharmacogn Res 12(5): 911–928. https://doi.org/10.56499/jppres23.1877_12.5.911  [913 Kb] [ABSTRACT]


10.– Original Article

Yasmiwar Susilawati, Raden Bayu Indradi, Aiyi Asnawi, Ellin Febrina (2024) **Molecular docking and dynamics studies of 8,9-dimethoxy ellagic acid contained in *Peperomia pellucida* (L.) Kunth against various diabetes mellitus receptors.** [Estudios de acoplamiento y dinámica molecular del ácido 8,9-dimetoxielágico contenido en *Peperomia pellucida* (L.) Kunth frente a varios receptores de diabetes mellitus]. J Pharm Pharmacogn Res 12(5): 929–942. https://doi.org/10.56499/jppres23.1936_12.5.929  [912 Kb] [ABSTRACT]


11.– Original Article

Ho Anh Hien, Nguyen Minh Tam, Dirk Devroey, Stefan Heytens, Vo Tam, Tran Binh Thar Vo Nu Hong Duc, Dang Thi Thanh Nha, Doan Pham Phuoc Long, Nguyen Vu Phor Huynh Van Minh, Hoang Anh Tien (2024) **Hypertension knowledge and its associated factors among hypertensive patients in primary care settings in Central Vietnam: cross-sectional study.** | [Conocimiento de la hipertensión y sus factores asociados entre pacientes hipertensos en entornos de atención primaria en el centro de Vietnam. Un estudio transversal]. J Pharm Pharmacogn Res 12(5): 943-955. https://doi.org/10.56499/jppres24.1955_12.5.943  [509 Kb] [ABSTRACT]


12.- Review

Jonathan Christianto Sutadji, Dian Anggraini Permatasari Musalim, David Setyo Bu Jennifer Susanto, Fanny Gunawan, Chaq El Chaq Zamzam Multazam, Citrawati Dyr Kencono Wungu (2024) **SS-31 protects diabetic nephropathy progression: systematic review of *in vivo* and *in vitro* studies.** | [El SS-31 protege la progresión de nefropatía diabética: Una revisión sistemática de estudios *in vivo* e *in vitro*]. J Pharm Pharmacogn Res 12(5): 956-971. https://doi.org/10.56499/jppres23.1904_12.5.956  [547 Kb] [ABSTRACT]

13.- Original Article


Suci Nar Vikasari, Elin Yulinh Sukandar, Tri Suciati, I Ketut Adnyana (2024) **An anti-inflammatory effect of the mixture of *Ageratum conyzoides* L. extract and eggshell membrane hydrolysates and *in silico* active compound predictions.** | [Efecto antiinflamatorio de la mezcla de extracto de *Ageratum conyzoides* L. e hidrolizados de membrana de cáscara de huevo, y predicción *in silico* de compuestos activos]. J Pharm Pharmacogn Res 12(5): 972-993. https://doi.org/10.56499/jppres24.1956_12.5.972  [1.10 Mb] [ABSTRACT]

14.- Review

Suleiman Zakari, Wisdom D. Cleanclay, Mercy Bella-Omunagbe, Hajara Zakari Celestine O. Ogbu, Daniel Ejim Uti, Olubanke O. Ogunlana (2024) **The role of SRC-3 in prostate cancer progression and implications for therapeutic targeting: systematic review.** | [El papel de SRC-3 en la progresión del cáncer de próstata y sus implicaciones para la orientación terapéutica: Una revisión sistemática]. J Pharm Pharmacogn Res 12(5): 994-1007. https://doi.org/10.56499/jppres23.1916_12.5.994  [741 Kb] [ABSTRACT]

15.- Original Article

Dini Kesuma, Galih Satrio Putra, Yahmin Yahmin, Sumari Sumari, Anisa Oktaviana Pu Farida Anwari, Novynanda Salmasfatah, Melanny Ika Sulistyowaty (2024) **Hansen's analysis by QSAR model of curcumin and eight of its transformed derivatives with**

antimicrobial activity against *Staphylococcus aureus*. | [Análisis Hansch mediante modelo QSAR de curcumina y ocho de sus derivados transformados con actividad antimicrobiana contra *Staphylococcus aureus*]. J Pharm Pharmacogn Res 12(1):1008-1020. https://doi.org/10.56499/jppres24.1945_12.5.1008  [914 Kb] [ABSTRACT]

© 2024 Journal of Pharmacy & Pharmacognosy Research (JPPRes)



[Home](#) [About](#) [Archive](#) [Authors](#) [Reviewers](#) [Events](#) [Blog](#)

[!\[\]\(e78f798d4ea5c530c9db49e7d26e6b95_img.jpg\) Twitter](#) [!\[\]\(034433b90593e82e5460e34e3ed48e9b_img.jpg\) LinkedIn](#) [!\[\]\(5f24500834b50a8307ffe63e419281a9_img.jpg\) Facebook](#)

© 2013–2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license–Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by **AVAGAX Studio**

Journal of Pharmacy and Pharmacognosy Research

COUNTRY

[Chile](#)



Universities and research
institutions in Chile



Media Ranking in Chile

SUBJECT AREA AND CATEGORY

[Health Professions](#)
[Pharmacy](#)

[Medicine](#)
[Complementary and Alternative
Medicine](#)

[Pharmacology, Toxicology and
Pharmaceutics](#)
[Drug Discovery](#)
[Pharmaceutical Science](#)
[Pharmacology](#)

PUBLISHER

[Asociacion Academica de Ciencias
Farmaceuticas de Antofagasta \(ASOCIFA\)](#)

H-INDEX

17

PUBLICATION TYPE

Journals

ISSN

07194250

COVERAGE

2013-2023

INFORMATION

[Homepage](#)

[How to publish in this journal](#)


editor@jppres.com

SCOPE

The Journal of Pharmacy & Pharmacognosy Research (JPPRes) is an international, specialized and peer-reviewed open access journal, under the auspices of AVAGAX – Diseño, Publicidad y Servicios Informáticos, which publishes studies in the pharmaceutical and herbal fields concerned with the physical, botanical, chemical, biological, toxicological properties and clinical applications of molecular entities, active pharmaceutical ingredients, devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture, evaluation and marketing. This journal publishes research papers, reviews, commentaries and letters to the editor as well as special issues and review of pre-and post-graduate thesis from pharmacists or professionals involved in Pharmaceutical [Sciences](#) or Pharmacognosy.

 Join the conversation about this journal

<p>1 Advances in Pharmacological and Pharmaceutical Sciences GBR</p> <p>70% similarity</p>	<p>2 Phytomedicine Plus NLD</p> <p>70% similarity</p>	<p>3 Journal of Applied Pharmaceutical Science IND</p> <p>67% similarity</p>	<p>4 Journal of Natural Remedies IND</p> <p>67% similarity</p>	<p>5 Journal of HerbMed Pharmacology IRN</p> <p>66% similarity</p>
--	---	--	--	--



Journal of Pharmacy and Pharmacognosy Research

Q2 Pharmacy best quartile

SJR 2023 0.29

powered by scimagojr.com

← Show this widget in your own website

Just copy the code below and paste within your html code:

SCImago Graphica

Explore, visually communicate and make sense of data with our new data visualization tool.



Metrics based on Scopus® data as of March 2024



Gabino Garrido Garrido 3 years ago

Dear Melanie,
Thank you for your kind and quick reply.
Sincerely

reply



Gabino Garrido Garrido 3 years ago

Dear Scimagojr,
Please, some time ago I contacted Scimago in this way to see the possibility of incorporating my journal (Journal of Pharmacy and Pharmacognosy Research) into the Pharmacy category. I have not received any responses.

Hopefully, you can answer me if this is the appropriate way to make such a request.

[Physics-Themed Jewelry](#)

Thank you!
Best regards.
Gabino Garrido,
editor-in-chief

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Gabino,
Thank you for contacting us.
SJR is a portal with scientometric indicators of journals indexed in Scopus. All the metadata (Title, ISSN, Publisher, Category, etc.) have been provided by Scopus /Elsevier and SCImago doesn't have the authority over these data which are property of Scopus/ Elsevier. SCImago is not allowed to do any changes of the metadata unless Scopus authorizes it expressly. SCImago has a signed agreement that limits our performance to the generation of scientometric indicators derived from the metadata sent in the last update. Keep also in mind that the SJR is a static image (the update is made only one time per year) of a database (Scopus) which is changing every day.
Therefore, we suggest you contact Scopus support regarding this matter here:
https://service.elsevier.com/app/answers/detail/a_id/14883/kw/scimago/supporthub/scopus/
Best Regards,
SCImago Team

Leave a comment

Name

Email
(will not be published)

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2024. Data Source: Scopus®

EST MODUS IN REBUS
Hicrono (Online 1.1.106)

Legal Notice

Privacy Policy



Source details

Journal of Pharmacy and Pharmacognosy Research

Open Access ⓘ

Years currently covered by Scopus: from 2013 to 2024

Publisher: Asociacion Academica de Ciencias Farmaceuticas de Antofagasta (ASOCIFA)

E-ISSN: 0719-4250

Subject area:

Health Professions: Pharmacy

Medicine: Complementary and Alternative Medicine

Pharmacology, Toxicology and Pharmaceutics: Pharmaceutical Science

Pharmacology, Toxicology and Pharmaceutics: Pharmacology

View all ▾

Source type: Journal

View all documents >

Set document alert

Save to source list

CiteScore CiteScore rank & trend Scopus content coverage

CiteScore 2023 ▾

3.0 = $\frac{913 \text{ Citations } 2020 - 2023}{308 \text{ Documents } 2020 - 2023}$

Calculated on 05 May, 2024

CiteScoreTracker 2024 ⓘ

2.9 = $\frac{1,001 \text{ Citations to date}}{347 \text{ Documents to date}}$

Last updated on 05 September, 2024 • Updated monthly

CiteScore rank 2023 ⓘ

Category	Rank	Percentile
Health Professions		
Pharmacy	#11/45	76th
Medicine		
Complementary and Alternative Medicine	#47/105	55th
Pharmacology		

View CiteScore methodology > CiteScore FAQ > Add CiteScore to your site

CiteScore 2023
3.0 ⓘ

SJR 2023
0.291 ⓘ

SNIP 2023
0.554 ⓘ

About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

ELSEVIER

[Terms and conditions ↗](#) [Privacy policy ↗](#) [Cookies settings](#)

All content on this site: Copyright © 2024 Elsevier B.V. ↗, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.

 RELX™